newsfilter
← Latest News
GlobeNewswire·

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS) relapses following